3/13
06:08 pm
rlmd
Relmada Therapeutics (RLMD) was given a new $10.00 price target by Mizuho.
Medium
Report
Relmada Therapeutics (RLMD) was given a new $10.00 price target by Mizuho.
3/12
10:33 pm
rlmd
Why Relmada Therapeutics (RLMD) Is Up 38.8% After $160M Raise And Positive NDV-01 Phase 2 Data [Yahoo! Finance]
Medium
Report
Why Relmada Therapeutics (RLMD) Is Up 38.8% After $160M Raise And Positive NDV-01 Phase 2 Data [Yahoo! Finance]
3/12
07:00 am
rlmd
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026
Low
Report
Relmada Therapeutics to Report Fourth Quarter 2025 Financial Results on Thursday, March 19, 2026
3/10
11:41 am
rlmd
A Look At Relmada Therapeutics (RLMD) Valuation After NDV-01 Phase 2 Update And US$160 Million Private Placement [Yahoo! Finance]
Medium
Report
A Look At Relmada Therapeutics (RLMD) Valuation After NDV-01 Phase 2 Update And US$160 Million Private Placement [Yahoo! Finance]
3/9
07:17 pm
rlmd
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today [Yahoo! Finance]
Medium
Report
50% and 61% Gains in a Single Day: Why XENE and RLMD Soared Today [Yahoo! Finance]
3/9
04:42 pm
rlmd
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
Medium
Report
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference [Yahoo! Finance]
3/9
04:30 pm
rlmd
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
Medium
Report
Relmada Therapeutics to Present at the Leerink Partners Global Healthcare Conference
3/9
07:32 am
rlmd
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer [Yahoo! Finance]
High
Report
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer [Yahoo! Finance]
3/9
07:05 am
rlmd
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
High
Report
Relmada Therapeutics Announces Oversubscribed $160.0 Million Private Placement Financing
3/9
07:00 am
rlmd
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
High
Report
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
3/4
05:51 am
rlmd
Relmada Therapeutics (RLMD) was upgraded by Lucid Cap Mkts to "strong-buy".
Medium
Report
Relmada Therapeutics (RLMD) was upgraded by Lucid Cap Mkts to "strong-buy".
2/26
12:07 pm
rlmd
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
Medium
Report
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
1/30
06:07 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
1/29
07:41 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Zacks Research to a "hold" rating.
Low
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Zacks Research to a "hold" rating.
1/23
08:04 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $8.00 price target on the stock.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $8.00 price target on the stock.
1/12
07:20 am
rlmd
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications [Yahoo! Finance]
Medium
Report
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications [Yahoo! Finance]
1/12
07:00 am
rlmd
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
Low
Report
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
12/23
09:37 am
rlmd
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Low
Report
Relmada Therapeutics (NASDAQ:RLMD) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
12/21
08:06 pm
rlmd
Relmada Therapeutics (NASDAQ:RLMD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Medium
Report
Relmada Therapeutics (NASDAQ:RLMD) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating on the stock.